XNCR Stock - Xencor, Inc.
Unlock GoAI Insights for XNCR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $110.49M | $174.62M | $164.58M | $275.11M | $122.69M |
| Gross Profit | $110.49M | $174.62M | $164.58M | $275.11M | $-47,108,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -38.4% |
| Operating Income | $-178,408,000 | $-132,362,000 | $-82,473,000 | $43.77M | $-76,797,000 |
| Net Income | $-232,618,000 | $-133,133,000 | $-55,181,000 | $82.63M | $-69,333,000 |
| Net Margin | -210.5% | -76.2% | -33.5% | 30.0% | -56.5% |
| EPS | $-3.58 | $-2.08 | $-0.93 | $1.42 | $-1.11 |
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| October 29th 2025 | Barclays | Upgrade | Overweight | $23 |
| September 17th 2025 | Barclays | Resumed | Underweight | $6 |
| September 3rd 2025 | BofA Securities | Downgrade | Neutral | $12 |
| April 21st 2025 | William Blair | Initiation | Outperform | - |
| December 12th 2024 | Wells Fargo | Initiation | Overweight | $37 |
| December 2nd 2024 | Piper Sandler | Upgrade | Overweight | $30← $20 |
| April 16th 2024 | BTIG Research | Reiterated | Buy | $38← $56 |
| February 28th 2024 | Piper Sandler | Downgrade | Neutral | $24← $37 |
| May 19th 2023 | BofA Securities | Initiation | Buy | $42 |
| December 6th 2022 | Cowen | Initiation | Outperform | - |
| October 13th 2022 | Raymond James | Upgrade | Strong Buy | $58 |
| September 21st 2022 | JP Morgan | Initiation | Overweight | $37 |
| July 6th 2022 | Canaccord Genuity | Resumed | Buy | $50 |
Earnings History & Surprises
XNCREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.64 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.72 | $-0.08 | +88.9% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.78 | $-0.41 | +47.4% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.63 | $-0.66 | -4.8% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.81 | $-0.62 | +23.5% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.98 | $-0.71 | +27.6% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.85 | $-1.07 | -25.9% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.76 | $-1.11 | -46.1% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $0.36 | $-0.31 | -186.1% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.77 | $-0.40 | +48.1% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.91 | $-0.37 | +59.3% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.75 | $-1.02 | -36.0% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.83 | $-0.20 | +75.9% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.77 | $-0.55 | +28.6% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.45 | $-0.57 | -26.7% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.61 | $0.39 | +163.9% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-0.10 | $1.21 | +1310.0% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.75 | $-0.69 | +8.0% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.56 | $0.87 | +255.4% | ✓ BEAT |
Latest News
Xencor Secures New US Patent, Extending Ultomiris Royalties By Three Years And Unlocking Up To $120M In Additional Revenue
📈 PositiveTruist Securities Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $29
📈 PositiveJP Morgan Maintains Overweight on Xencor, Lowers Price Target to $18
📈 PositiveRBC Capital Maintains Outperform on Xencor, Raises Price Target to $19
📈 PositiveCantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $42
📈 PositiveXencor Q3 EPS $(0.08) Beats $(0.69) Estimate, Sales $21.000M Miss $27.154M Estimate
➖ NeutralRBC Capital Maintains Outperform on Xencor, Raises Price Target to $18
📈 PositiveXencor Presents Initial Results From Ongoing Phase 1 Dose-Escalation Study Of XmAb819, ENPP3 X CD3 T-Cell Engaging Bispecific Antibody, In Patients With Advanced ccRCC, At AACR-NCI-EORTC
📈 PositiveXencor slides amid plans for early-stage trial data for kidney cancer drug
📉 NegativeXencor To Present Initial Results From Ongoing Phase 1 Dose-Escalation Study Of Xmab819 In Patients With ccRCC At AACR-NCI-EORTC Conference 2025
➖ NeutralCantor Fitzgerald Assumes Xencor at Overweight, Announces Price Target of $40
📈 PositiveB of A Securities Downgrades Xencor to Neutral, Lowers Price Target to $12
➖ NeutralWedbush Reiterates Outperform on Xencor, Maintains $26 Price Target
📈 PositiveRBC Capital Maintains Outperform on Xencor, Lowers Price Target to $15
➖ NeutralFrequently Asked Questions about XNCR
What is XNCR's current stock price?
What is the analyst price target for XNCR?
What sector is Xencor, Inc. in?
What is XNCR's market cap?
Does XNCR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to XNCR for comparison